What's in S.L.A. Pharma AG's pipeline?

S.L.A. Pharma AG has 3 drugs in our index: 0 marketed, 0 filed, 2 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with S.L.A. Pharma AG's portfolio?

Top competitors by shared drug class: Addpharma Inc., Ain Shams University, Bioprojet, Boryung Pharmaceutical Co., Ltd, Bristol-Myers Squibb.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/s-l-a-pharma-ag.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

S.L.A. Pharma AG — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

S.L.A. Pharma AG pipeline: 0 marketed, 0 filed, 2 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Diltiazem hydrochloride 4% cream	Diltiazem hydrochloride 4% cream	phase 3	Calcium channel blocker	L-type calcium channels	Dermatology / Pain Management
Eicosapentaenoic acid gastro-resistant capsules	Eicosapentaenoic acid gastro-resistant capsules	phase 3	Omega-3 fatty acid	Multiple targets including triglyceride metabolism and inflammatory pathways	Cardiovascular

Therapeutic area mix

Cardiovascular · 1
Dermatology / Pain Management · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Addpharma Inc. · 1 shared drug class
Ain Shams University · 1 shared drug class
Bioprojet · 1 shared drug class
Boryung Pharmaceutical Co., Ltd · 1 shared drug class
Bristol-Myers Squibb · 1 shared drug class
Estudios Clínicos Latino América · 1 shared drug class
GlaxoSmithKline · 1 shared drug class
· 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for S.L.A. Pharma AG:

Cite this brief

Drug Landscape (2026). S.L.A. Pharma AG — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/s-l-a-pharma-ag. Accessed 2026-05-17.